Chenglan Li
Second Military Medical University
5 Papers
19 Citations
Chenglan Li is an academic researcher from Second Military Medical University. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
TL;DR: The first generation of lanosterol 14α-demethylase (CYP51)-histone deacetylase (HDAC) dual inhibitors were designed, which exhibited potent antifungal activity against azole-resistant clinical isolates and were highly active both in vitro and in vivo to treat azolesole- resistant candidiasis.
55
Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
TL;DR: In this article, the authors designed the first CYP51/HDAC dual inhibitors with potent activity against resistant Candida albicans infections, which showed potent in vitro and in vivo antifungal activity against C.tropicalis and C.neoformans.
27
Targeting fungal virulence factor by small molecules: Structure-based discovery of novel secreted aspartic protease 2 (SAP2) inhibitors
TL;DR: Indolone derivative 24a, a promising lead compound for the discovery of novel antifungal agents, showed potent SAP2 inhibitory activity and showed potent in-vivo efficacy in a murine model of invasive candidiasis.
16
Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
Qi-Sheng Ma,Yi Fan Zhang,Chenglan Li,Weixing Zhang,Lu-Jiang Yuan,Jinlin Niu,Jian-Ying Song,Sai-Yang Zhang,Hong-Min Liu +8 more
TL;DR: In this paper , a series of tranylcypromine-based derivatives were designed and synthesized, and compound 12u exhibited the most potent inhibitory potency on LSD1 (IC50 = 25.3 nM), and also displayed good antiproliferative effects on MGC-803, KYSE450 and HCT-116 cells with IC50 values of 14.3, 22.8 and 16.3 μM, respectively.
5
Patent
Triazole CYP51-HDAC double-target antifungal compound as well as preparation method and application thereof
Chunquan Sheng,Liu Na,Han Guiyan,Chenglan Li,Jie Tu,Huang Yahui +5 more
- 30 Jun 2020
TL;DR: In this paper, a triazole CYP51-HDAC double-target antifungal compound was disclosed, which has a structural general formula, wherein R is selected from one of the structures disclosed in the invention.